Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

MLA

Hamid Sayar, et al. “Phase 3 Results for Vosaroxin/Cytarabine in the Subset of Patients ≥60 Years Old with Refractory/Early Relapsed Acute Myeloid Leukemia.” Haematologica, vol. 103, May 2018, pp. e514–18. EBSCOhost, https://doi.org/10.3324/haematol.2018.191361.

APA

Hamid Sayar, Heinz A. Horst, Stephen A. Strickland, Arnaud Pigneux, Gary J. Schiller, Michael Craig, Robert K. Stuart, Miklos Egyed, Renee Ward, Elias Jabbour, Jennifer A. Smith, Hagop M. Kantarjian, Jorge E. Cortes, Gary Acton, Utz Krug, Angelo Michele Carella, Farhad Ravandi, Ellen K. Ritchie, Judith A. Fox, … Christian Recher. (2018). Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica, 103, e514–e518. https://doi.org/10.3324/haematol.2018.191361

Chicago

Hamid Sayar, Heinz A. Horst, Stephen A. Strickland, Arnaud Pigneux, Gary J. Schiller, Michael Craig, Robert K. Stuart, et al. 2018. “Phase 3 Results for Vosaroxin/Cytarabine in the Subset of Patients ≥60 Years Old with Refractory/Early Relapsed Acute Myeloid Leukemia.” Haematologica 103 (May): e514–18. doi:10.3324/haematol.2018.191361.